PDCD1 and intrahepatic cholangiocarcinoma: These results provide a rationale for the combination of an AXL/MERTK inhibitor and anti–PD-1 antibody in ICC, and these findings might ultimately help identify a more effective combination regimen to elicit stronger antitumor responses.